Pharmaceutical Growth Opportunities in Brazil, Russia, India and China - Healthcare reform, market dynamics and key players

Positive economic growth, stabilizing political structures, growing patient populations and increasing direct foreign investment in the emerging markets of Brazil, Russia, India and China (BRIC) are creating significant opportunities for pharmaceutical companies to expand into these markets and maximize future revenue potential. Pharmaceutical sales across the BRIC economies grew by 22.3%in 2005, compared to single digit growth in the major markets of the US, Europe and Japan. This new report provides an in-depth insight into the competitive dynamics of the BRIC markets. The political and regulatory environments are evaluated and healthcare systems assessed, enabling you to understand the determinants crucial to your success in these high growth markets. Benchmark your growth strategies against the top pharmaceutical companies operating in the BRIC markets, align your portfolio with future market opportunity and identify lucrative partnering opportunities to ensure you maximize the potential from these promising markets.

This report will provide you with:

Gold standard IMS data on the cardiovascular, cancer, respiratory, anti-infectives, and CNS markets in the BRIC countries and forecasts to 2011, enabling you to assess current market opportunities and align your portfolio to exploit future growth opportunities.

An understanding of how economic, political and social changes are impacting market development, enabling you to analyze market opportunity and formulate successful entry strategies.

A detailed examination of the factors impacting the penetration of generics versus branded products across each of the BRIC markets, including the enforcement of intellectual property rights, cost containment and access to medicines.

In depth analysis of the competitive dynamics of each of the BRIC markets and detailed profiles of leading domestic and multinational players, including Sanofi-Aventis, Gedeon Richter, Aché Labs, Cipla and HLJ. Harbin.

Benchmark your growth strategies against the top pharmaceutical companies operating in the BRIC markets, align your portfolio with future market opportunity and identify lucrative partnering opportunities to ensure you maximize the potential from these promising markets.

Published: August 2006 Format PDF
Table of Contents
Full Table of Contents (PDF)
Price: $2,875.00 / GBP1,897.50